| Outcome Measures: |
Primary: Difference in mean Hb level change during the evaluation period from baseline (evaluation period - baseline) between study arm and control arm, Hb level during the evaluation period is the mean of the Hb levels at Week 20, Week 22 and End of Treatment (Week 24 or at discontinuation)., baseline and Week 20 to 24|Difference in mean Hb level between study arm and control arm during the evaluation period, Hb level during the evaluation period is the mean of the Hb levels at Week 20, Week 22 and End of Treatment (Week 24 or at discontinuation)., baseline and Week 20 to 24 | Secondary: Proportion of subjects with Hb level within the range of baseline ± 1.0 g/dL at Week 4, Week4|Proportion of subjects with mean Hb level of ≥10.0 g/dL and <12.0 g/dL during the evaluation period, Week 20, 22, 24|Hb level at each Visit, Week 2, 4, 8, 12, 16, 20, 22, 24|Change from baseline in Hb level at each Visit, Week 0, 2, 4, 8, 12, 16, 20, 22, 24
|
